Gene Expression analysis of castration-resistant prostate cancer bone metastases
Expression microarray · human · 30 samples
- What it is
- Expression microarrayGene activity read on a chip (the older technology that RNA-seq replaced).
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 30 samples: 30 × Bone met sampleGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed expression table (series matrix) and the array files, from NCBI.
Direct links to NCBI, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need.
Whole study · RAW.tar
Everything the authors deposited as one archive (GSE29650_RAW.tar), including the raw array or instrument files. Can be large; the picker in step 2 takes just the samples you need.
What the files usually look like: For arrays the series matrix is normally the normalised expression table you want; the raw array files (CEL and similar) are in the RAW.tar.
Also filed as BioProject PRJNA141237. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 1 replicated groups read from 30 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM735054 Bone met sample 1 Bone met sample
- GSM735055 Bone met sample 2 Bone met sample
- GSM735056 Bone met sample 3 Bone met sample
- GSM735057 Bone met sample 4 Bone met sample
- GSM735058 Bone met sample 5 Bone met sample
- GSM735059 Bone met sample 6 Bone met sample
- GSM735060 Bone met sample 7 Bone met sample
- GSM735061 Bone met sample 8 Bone met sample
- GSM735062 Bone met sample 9 Bone met sample
- GSM735063 Bone met sample 10 Bone met sample
- GSM735064 Bone met sample 11 Bone met sample
- GSM735065 Bone met sample 12 Bone met sample
- GSM735066 Bone met sample 13 Bone met sample
- GSM735067 Bone met sample 14 Bone met sample
- GSM735068 Bone met sample 15 Bone met sample
- GSM735069 Bone met sample 16 Bone met sample
- GSM735070 Bone met sample 17 Bone met sample
- GSM735071 Bone met sample 18 Bone met sample
- GSM735072 Bone met sample 19 Bone met sample
- GSM735073 Bone met sample 20 Bone met sample
- GSM735074 Bone met sample 21 Bone met sample
- GSM735075 Bone met sample 22 Bone met sample
- GSM735076 Bone met sample 23 Bone met sample
- GSM735077 Bone met sample 24 Bone met sample
- GSM735078 Bone met sample 25 Bone met sample
- GSM735079 Bone met sample 26 Bone met sample
- GSM735080 Bone met sample 27 Bone met sample
- GSM735081 Bone met sample 28 Bone met sample
- GSM735082 Bone met sample 29 Bone met sample
- GSM735083 Bone met sample 30 Bone met sample
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares prostate
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE339157 Bulk RNA sequencing of prostate cancer (PCa) primary tumors and metastases: Epworth Clinical Cohort 48 samples shares metastases, prostate
- GSE325471 The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication 12 samples shares castration-resistant, prostate
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.